前列腺癌[18F]PSMA-1007 PET/CT中不确定性骨病灶的恶性与PSMA表达评估——PET引导活检的单中心经验
该单中心回顾性分析对10例前列腺癌患者的11个[18F]PSMA-1007 PET/CT示踪剂高摄取不确定性骨病灶行PET引导活检,1/11(9.1%)证实为前列腺癌骨转移且PSMA强表达,10/11(90.9%)为无PSMA表达的无异常骨组织,所有病灶均无CT形态学对应改变。
要点
- 11个不确定性骨病灶中仅1个(9.1%)经活检证实为前列腺癌骨转移。
- 10个(90.9%)良性病灶免疫组化均未见PSMA表达,提示非PSMA介导的摄取机制。
- 所有不确定性骨病灶在CT上均无形态学对应改变。
核心结论
- 该队列活检显示少数但不可忽视比例的不确定性骨摄取为真转移。
- 经证实为良性的病灶免疫组化未见PSMA表达,提示存在非PSMA介导的[18F]PSMA-1007高摄取,其原因仍不明确。
- 阅片者须谨慎解读此类病灶,以减少错误分期及后续治疗的风险。
- PET引导活检,尤其在CT无形态学改变时,可为澄清此类病灶的有用方法。
研究设计与样本
- 单中心回顾性分析,纳入10例因既往[18F]PSMA-1007 PET/CT发现不确定性骨摄取而转诊行PET引导活检的前列腺癌患者。
- 对上述10例患者的11个PSMA高摄取骨病灶行[18F]PSMA-1007 PET引导活检。
- 活检材料行组织分型分析,并行前列腺特异性膜抗原(PSMA)表达免疫组化检测。
- 影像由两名经验丰富医师共识阅片,分析病灶临床特征与示踪剂摄取。
主要发现
- 11个活检病灶中1个(9.1%)证实为前列腺癌骨转移,伴PSMA强表达。
- 11个病灶中10个(90.9%)为无异常骨组织,免疫组化无PSMA表达证据。
- 全部活检骨病灶中,8个在PET/CT上视觉分类为恶性高风险(SUVmean 12.0 ± 8.1;SUVmax 18.8 ± 13.1)。
- 3个视觉分类为不确定(SUVmean 4.6 ± 2.1;SUVmax 7.2 ± 3.0),0个为低风险。
- 所有不确定性骨摄取均无CT对应表现。
关键数值与推荐
- 视觉分类为恶性高风险的8个病灶:SUVmean 12.0 ± 8.1,SUVmax 18.8 ± 13.1。
- 视觉分类为不确定的3个病灶:SUVmean 4.6 ± 2.1,SUVmax 7.2 ± 3.0。
- 视觉分类为低风险的病灶为0个。
临床怎么用
- 作者认为,阅片者须谨慎解读[18F]PSMA-1007 PET/CT中的不确定性骨摄取,以减少错误分期及后续治疗的风险。
- 作者认为,PET引导活检,尤其在CT无形态学改变时,可为澄清此类病灶的有用方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are frequently observed in patients undergoing [18F]PSMA-1007 PET/CT for the detection of prostate cancer (PC). Such foci can pose diagnostic conundrums and risk incorrect staging. The aim of this short communication is to share the results of PET-guided biopsies of such foci. METHODS: A retrospective analysis revealed 10 patients who were referred to our department for PET-guided biopsy of UBU visible in a previous [18F]PSMA-1007 PET/CT. [18F]-PSMA-1007 PET-guided biopsy was conducted for 11 PSMA-avid bone foci in these 10 patients. The biopsy materials were analysed for tissue typing, and immunohistochemistry (IHC) was performed for prostate-specific-membrane-antigen (PSMA) expression. The scans were analysed by two experienced physicians in a consensus read for clinical characteristics and radiopharmaceutical uptake of foci. RESULTS: One out of 11 (9.1%) of the foci biopsied was confirmed as bone metastasis of PC with intense PSMA-expression, while 10/11 (90.9%) foci were revealed to be unremarkable bone tissue without evidence of PSMA expression at IHC. Amongst all bone foci assessed by biopsy, eight were visually classified as being at high risk of malignancy in the PET/CT (SUVmean 12.0 ± 8.1; SUVmax 18.8 ± 13.1), three as equivocal (SUVmean 4.6 ± 2.1; SUVmax 7.2 ± 3.0) and zero as low risk. No UBU had any CT correlate. CONCLUSIONS: This cohort biopsy revealed that a small but relevant number of UBU are true metastases. For those confirmed as benign, no PSMA expression at IHC was observed, suggesting a non-PSMA mediated cause for intensive [18F]PSMA-1007 uptake of which the reason remains unclear. Readers must interpret such foci with caution in order to reduce the risk of erroneous staging and subsequent treatment. PET-guided biopsy, particularly in the absence of morphological changes in the CT, can be a useful method to clarify such foci.
引用
- Vollnberg B, Alberts I, Genitsch V, et al. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022. PMID: 35482114. doi:10.1007/s00259-022-05745-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。